Novartis, Vertex and Ipsen extend pharma's M&A spree after 45 first-half acquisitions

Novartis, Vertex, Ipsen and United Therapeutics kick off second-half M&A activity with up to $12.6B in new deals, extending a 45-deal run from 2026's first half.

Raccontata daendpoints.news